FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Method of determining sensitivity of tumor cell growth to inhibition by EGFR kinase inhibitor is disclosed, which involves determining ERBB2 gene methylation status in tumor cell sample, reduced level of methylation ERBB2 gene means, that less than 50 % of possible methylation sites in part of ERBB2 gene are methylated, and indicates that growth of tumor cells is sensitive to inhibition by inhibitor EGFR. Method of detecting patient with malignant tumor is also described, favorable effect on which can have treatment with help of EGFR inhibitor. Method of selecting therapy for patient with malignant tumor is described. Invention extends range of methods for prediction of response to anticancer therapy.
EFFECT: method of determining ERBB2 gene overexpression in cell is disclosed.
31 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER | 2015 |
|
RU2739942C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
| METHOD FOR ANALYSING DISORDERS RELATED TO OVARIAN CARCINOMA | 2008 |
|
RU2511408C2 |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION | 2010 |
|
RU2553379C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| CANCER TREATMENT WITH TG02 | 2017 |
|
RU2749025C2 |
| IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT | 2011 |
|
RU2600828C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 | 2003 |
|
RU2338751C2 |
